QNCX
Quince Therapeutics, Inc.
NasdaqGSUSDEQUITY
DELAYED
Last price
33.93
▲ 1.82 (5.67%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
32.11
Prev close
32.11
Day high
34.09
Day low
32.57
Volume
9.54K
Market cap
—
P/E (TTM)
—
52W range
15.10 – 910.00
Trailing performance
Returnvs SPY
1W
-0.32%
+1.0%
1M
+85.61%
+81.9%
3M
+58.55%
+55.5%
6M
+13.10%
+2.0%
YTD
-94.94%
-107.2%
1Y
-89.59%
-109.6%
3Y
-86.85%
-161.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on QNCX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $35.38M | $18.59M | $9.45M | $25.18M | +90.3% |
| Selling, general & admin | $15.05M | $17.58M | $17.70M | $26.01M | -14.4% |
| Total operating expense | $50.43M | $36.17M | $27.14M | $51.19M | +39.4% |
| Operating income | -$50.43M | -$36.17M | -$27.14M | -$51.19M | -39.4% |
| Net interest income | $1.24M | $2.93M | $3.48M | $1.07M | -57.5% |
| Pre-tax income | -$80.77M | -$56.74M | -$31.58M | -$51.94M | -42.3% |
| Tax provision | $3.21M | $87.00K | -$197.00K | -$284.00K | +3,594.3% |
| Net income | -$83.98M | -$56.83M | -$31.39M | -$51.66M | -47.8% |
| Net income to common | -$83.98M | -$56.83M | -$31.39M | -$51.66M | -47.8% |
| Basic EPS | -336.00 | -262.00 | -168.00 | -308.00 | -28.2% |
| Diluted EPS | -336.00 | -262.00 | -168.00 | -308.00 | -28.2% |
| EBIT | -$50.43M | -$36.17M | -$27.14M | -$51.19M | -39.4% |
| EBITDA | -$50.29M | -$35.98M | -$26.82M | -$50.99M | -39.7% |
| Basic shares | 250.48K | 216.31K | 186.19K | 167.48K | +15.8% |
| Diluted shares | 250.48K | 216.31K | 186.19K | 167.48K | +15.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $5.81M | $6.21M | $20.75M | $44.58M | -6.5% |
| Cash & short-term investments | $17.75M | $40.78M | $75.06M | $90.18M | -56.5% |
| Total current assets | $22.90M | $44.04M | $77.44M | $93.75M | -48.0% |
| Property, plant & equipment | $1.05M | $813.00K | $619.00K | $684.00K | +28.9% |
| Goodwill & intangibles | $67.82M | $60.05M | $81.30M | $5.90M | +12.9% |
| Total assets | $93.52M | $114.48M | $167.90M | $103.91M | -18.3% |
| Total current liabilities | $43.23M | $7.28M | $9.57M | $3.07M | +493.9% |
| Current debt | $18.03M | — | — | — | — |
| Long-term debt | — | $14.32M | $13.43M | — | — |
| Total debt | $18.47M | $14.81M | $13.81M | $453.00K | +24.7% |
| Total liabilities | $129.24M | $84.33M | $82.82M | $3.32M | +53.2% |
| Retained earnings | -$460.45M | -$376.47M | -$319.64M | -$288.26M | -22.3% |
| Shareholder equity | -$35.71M | $30.15M | $85.08M | $100.59M | -218.5% |
| Working capital | -$20.33M | $36.76M | $67.87M | $90.68M | -155.3% |
| Net tangible assets | -$103.53M | -$29.90M | $3.79M | $94.69M | -246.3% |
| Shares issued | 278.63K | 220.01K | 214.87K | 180.68K | +26.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$83.98M | -$56.83M | -$31.39M | -$51.66M | -47.8% |
| Depreciation & amortisation | $142.00K | $186.00K | $322.00K | $204.00K | -23.7% |
| Stock-based compensation | $5.11M | $4.75M | $5.22M | $16.62M | +7.6% |
| Change in working capital | $12.84M | -$484.00K | $1.98M | -$9.83M | +2,753.5% |
| Operating cash flow | -$41.42M | -$31.90M | -$18.29M | -$44.04M | -29.8% |
| Capital expenditure | -$352.00K | -$257.00K | -$160.00K | -$133.00K | -37.0% |
| Investing cash flow | $23.23M | $21.91M | -$5.76M | $18.00M | +6.0% |
| Financing cash flow | $17.91M | -$4.78M | $143.00K | $707.00K | +475.1% |
| Free cash flow | -$41.78M | -$32.16M | -$18.45M | -$44.17M | -29.9% |
| End cash position | $5.81M | $6.21M | $20.75M | $44.58M | -6.5% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $6.84M | $12.60M | $8.08M | $6.55M | $8.14M | -45.7% |
| Selling, general & admin | $4.27M | $3.63M | $3.28M | $3.34M | $4.79M | +17.4% |
| Total operating expense | $11.11M | $16.24M | $11.36M | $9.89M | $12.93M | -31.6% |
| Operating income | -$11.11M | -$16.24M | -$11.36M | -$9.89M | -$12.93M | +31.6% |
| Net interest income | $160.00K | $227.00K | $300.00K | $311.00K | $406.00K | -29.5% |
| Pre-tax income | $30.57M | -$36.31M | -$13.49M | -$15.98M | -$14.98M | +184.2% |
| Tax provision | -$5.34M | $3.15M | -$46.00K | $67.00K | $47.00K | -269.7% |
| Net income | $35.91M | -$39.46M | -$13.44M | -$16.05M | -$15.03M | +191.0% |
| Net income to common | $35.91M | -$39.46M | -$13.44M | -$16.05M | -$15.03M | +191.0% |
| Basic EPS | 57.60 | — | -50.00 | -68.00 | -68.40 | — |
| Diluted EPS | 57.60 | — | -50.00 | -68.00 | -68.40 | — |
| EBIT | -$11.11M | -$16.24M | -$11.36M | -$9.89M | -$12.93M | +31.6% |
| EBITDA | -$11.08M | -$16.20M | -$11.33M | -$9.86M | -$12.90M | +31.6% |
| Basic shares | 459.52K | — | 269.76K | 233.43K | 219.71K | — |
| Diluted shares | 459.52K | — | 269.76K | 233.43K | 219.71K | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $18.16M | $5.81M | $6.45M | $16.83M | $7.77M | — | +212.7% |
| Cash & short-term investments | $18.16M | $17.75M | $26.29M | $34.71M | $31.60M | — | +2.3% |
| Total current assets | $25.58M | $22.90M | $29.20M | $37.34M | $33.83M | — | +11.7% |
| Property, plant & equipment | $965.00K | $1.05M | $1.10M | $1.08M | $941.00K | — | -7.9% |
| Goodwill & intangibles | $0 | $67.82M | $67.73M | $67.57M | $62.36M | — | -100.0% |
| Total assets | $26.62M | $93.52M | $109.90M | $117.21M | $107.09M | — | -71.5% |
| Total current liabilities | $8.77M | $43.23M | $26.04M | $7.47M | $8.36M | — | -79.7% |
| Current debt | — | $18.03M | $17.52M | — | — | — | — |
| Long-term debt | — | — | — | $16.99M | $15.27M | $14.32M | — |
| Total debt | $406.00K | $18.47M | $17.99M | $17.49M | $15.75M | — | -97.8% |
| Total liabilities | $10.95M | $129.24M | $108.84M | $105.47M | $88.51M | — | -91.5% |
| Retained earnings | -$424.54M | -$460.45M | -$420.99M | -$407.55M | -$391.50M | — | +7.8% |
| Shareholder equity | $15.67M | -$35.71M | $1.06M | $11.74M | $18.58M | — | +143.9% |
| Working capital | $16.81M | -$20.33M | $3.16M | $29.88M | $25.47M | — | +182.7% |
| Net tangible assets | $15.67M | -$103.53M | -$66.67M | -$55.83M | -$43.78M | — | +115.1% |
| Shares issued | 689.54K | 278.63K | 272.47K | 268.12K | 220.44K | — | +147.5% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $35.91M | -$39.46M | -$13.44M | -$16.05M | -$15.03M | — | +191.0% |
| Depreciation & amortisation | $36.00K | $39.00K | $36.00K | $35.00K | $32.00K | — | -7.7% |
| Stock-based compensation | $1.29M | $1.19M | $1.25M | $1.27M | $1.39M | — | +8.0% |
| Change in working capital | -$2.38M | $12.47M | $194.00K | -$1.87M | $2.05M | — | -119.1% |
| Operating cash flow | -$7.63M | -$10.48M | -$9.93M | -$11.41M | -$9.60M | — | +27.2% |
| Capital expenditure | — | -$4.00K | -$74.00K | -$126.00K | -$148.00K | -$133.00K | — |
| Investing cash flow | $12.00M | $8.07M | -$1.78M | $6.04M | $10.90M | — | +48.7% |
| Financing cash flow | $9.44M | $2.03M | $1.38M | $14.41M | $87.00K | — | +364.3% |
| Free cash flow | -$7.63M | -$10.48M | -$10.00M | -$11.54M | -$9.75M | — | +27.3% |
| End cash position | $18.16M | $5.81M | $6.45M | $16.83M | $7.77M | — | +212.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
32.87
+3.22% from price
SMA 20
28.77
+17.94% from price
SMA 50
22.48
+50.90% from price
SMA 100
23.27
+45.84% from price
SMA 200
190.47
-82.19% from price
EMA 12
31.63
+7.28% from price
EMA 26
28.09
+20.78% from price
EMA 50
27.28
+24.39% from price
RSI (14)
69.6
Neutral
MACD (12,26,9)
3.54
Hist 0.20
ATR (14)
2.65
7.81% of price
Realised vol 30D
74.0%
Annualised
Bollinger upper
38.95
20, 2σ
Bollinger lower
18.59
20, 2σ
50 / 200 cross
Death
22.48 vs 190.47
Trend bias
Below 200
-82.19%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.97
More volatile than market
Correlation to SPY
0.07
Largely independent
Realised vol 30D
74.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-98.2%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
2.65
7.81% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Craig-Hallum Initiates Quince Therapeutics at Buy With $68 Price Target
MT Newswires · 2d ago
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
GlobeNewswire · 9d ago
As Acasti Pharma Advances FDA Orphan-Designated GTX-102 Oral Mucosal Spray, New Report Maps 7MM Ataxia-Telangiectasia Treatment Landscape
GlobeNewswire · 9d ago
Reddit initiated, Caterpillar downgraded: Wall Street's top analyst calls
The Fly · 25d ago
Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board
GlobeNewswire · 54d ago
Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy
Insider Monkey · 82d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.